A Paradoxical Treatment for a Paradoxical Condition: Infliximab Use in Three Cases of Mycobacterial IRIS

Overview

Journal Clin Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2015 Sep 24

PMID 26394669

Citations 23

Authors

Denise C Hsu

Kimberly F Faldetta

Luxin Pei

Virginia Sheikh

Netanya S Utay

Gregg Roby

Adam Rupert

Anthony S Fauci

Irini Sereti

Affiliations

Soon will be listed here.

Abstract

The management of corticosteroid refractory immune reconstitution inflammatory syndrome (IRIS) is currently unclear. Infliximab administration was associated with clinical improvement without significant adverse events in 3 patients with mycobacterial IRIS. Immunologic and virologic responses to antiretroviral therapy were unaffected. Tumor necrosis factor blockade may be beneficial for IRIS and warrants further study in clinical trials.

Citing Articles

Successful rescue TNF-α blocking for - Related immune reconstitution inflammatory syndrome: A case report.

Bes-Berlandier H, Garzaro M, Rouzaud C, Bodard S, Bille E, Ficheux M Heliyon. 2024; 10(7):e29341.

PMID: 38623247 PMC: 11016716. DOI: 10.1016/j.heliyon.2024.e29341.

Current knowledge of the immune reconstitution inflammatory syndrome in Whipple disease: a review.

Song X, Duan R, Duan L, Wei L Front Immunol. 2023; 14:1265414.

PMID: 37901208 PMC: 10611461. DOI: 10.3389/fimmu.2023.1265414.

The use of TNF-α antagonists in tuberculosis to control severe paradoxical reaction or immune reconstitution inflammatory syndrome: a case series and literature review.

Armange L, Lacroix A, Petitgas P, Arvieux C, Piau-Couapel C, Poubeau P Eur J Clin Microbiol Infect Dis. 2023; 42(4):413-422.

PMID: 36795280 DOI: 10.1007/s10096-023-04564-2.

Trismus and voice change after starting tuberculosis treatment.

Rocco J, Hammoud D, Allen C, Galindo F, Laidlaw E, Sereti I IDCases. 2021; 26:e01307.

PMID: 34692416 PMC: 8517377. DOI: 10.1016/j.idcr.2021.e01307.

Potential disease trigger as a therapeutic option: infliximab for paradoxical reaction in tuberculosis of the central nervous system.

Briner M, Oberholzer M, Wagner F, Chan A BMJ Case Rep. 2021; 14(8).

PMID: 34340991 PMC: 8330559. DOI: 10.1136/bcr-2020-235511.

References

Wallis R, Kyambadde P, Johnson J, Horter L, Kittle R, Pohle M . A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS. 2004; 18(2):257-64. DOI: 10.1097/00002030-200401230-00015. View

Vidal C, Garau J . Systemic steroid treatment of paradoxical upgrading reaction in patients with lymph node tuberculosis. Clin Infect Dis. 2005; 41(6):915-6. DOI: 10.1086/432807. View

Belknap R, Reves R, Burman W . Immune reconstitution to Mycobacterium tuberculosis after discontinuing infliximab. Int J Tuberc Lung Dis. 2005; 9(9):1057-8. View

Arend S, Leyten E, Franken W, Huisman E, van Dissel J . A patient with de novo tuberculosis during anti-tumor necrosis factor-alpha therapy illustrating diagnostic pitfalls and paradoxical response to treatment. Clin Infect Dis. 2007; 45(11):1470-5. DOI: 10.1086/522993. View

Blackmore T, Manning L, Taylor W, Wallis R . Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. Clin Infect Dis. 2008; 47(10):e83-5. DOI: 10.1086/592695. View

Wallis R, van Vuuren C, Potgieter S . Adalimumab treatment of life-threatening tuberculosis. Clin Infect Dis. 2009; 48(10):1429-32. DOI: 10.1086/598504. View

Sereti I, Rodger A, French M . Biomarkers in immune reconstitution inflammatory syndrome: signals from pathogenesis. Curr Opin HIV AIDS. 2010; 5(6):504-10. PMC: 3023985. DOI: 10.1097/COH.0b013e32833ed774. View

Solovic I, Sester M, Gomez-Reino J, Rieder H, Ehlers S, Milburn H . The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J. 2010; 36(5):1185-206. DOI: 10.1183/09031936.00028510. View

Mahnke Y, Greenwald J, DerSimonian R, Roby G, Antonelli L, Sher A . Selective expansion of polyfunctional pathogen-specific CD4(+) T cells in HIV-1-infected patients with immune reconstitution inflammatory syndrome. Blood. 2012; 119(13):3105-12. PMC: 3321870. DOI: 10.1182/blood-2011-09-380840. View

10.

Jorge J, Graciela C, Pablo A, Luis S . A life-threatening central nervous system-tuberculosis inflammatory reaction nonresponsive to corticosteroids and successfully controlled by infliximab in a young patient with a variant of juvenile idiopathic arthritis. J Clin Rheumatol. 2012; 18(4):189-91. DOI: 10.1097/RHU.0b013e318258b725. View

11.

ODowd C, Kewin P, Morris J, Cotton M . Tuberculosis complicated by immune reconstitution inflammatory syndrome in a patient on anti-TNFα therapy for Crohn's disease. BMJ Case Rep. 2012; 2011. PMC: 3063288. DOI: 10.1136/bcr.09.2010.3376. View

12.

Skerry C, Harper J, Klunk M, Bishai W, Jain S . Adjunctive TNF inhibition with standard treatment enhances bacterial clearance in a murine model of necrotic TB granulomas. PLoS One. 2012; 7(6):e39680. PMC: 3384606. DOI: 10.1371/journal.pone.0039680. View

13.

Lee H, Lee Y, Lee S, Choi S, Kim Y, Woo J . Adalimumab treatment may replace or enhance the activity of steroids in steroid-refractory tuberculous meningitis. J Infect Chemother. 2011; 18(4):555-7. DOI: 10.1007/s10156-011-0334-y. View

14.

Dorhoi A, Kaufmann S . Tumor necrosis factor alpha in mycobacterial infection. Semin Immunol. 2014; 26(3):203-9. DOI: 10.1016/j.smim.2014.04.003. View

15.

Namale P, Abdullahi L, Fine S, Kamkuemah M, Wilkinson R, Meintjes G . Paradoxical TB-IRIS in HIV-infected adults: a systematic review and meta-analysis. Future Microbiol. 2015; 10(6):1077-99. DOI: 10.2217/fmb.15.9. View